BiotechTube

SAGE-718 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease

Trial Timeline

Jan 26, 2022 → Oct 3, 2024

NCT ID
NCT05107128

About SAGE-718 + Placebo

SAGE-718 + Placebo is a phase 2 stage product being developed by Supernus Pharmaceuticals for Huntington's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05107128. Target conditions include Huntington's Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (5)

NCT IDPhaseStatus
NCT05358821Phase 2Completed
NCT05107128Phase 2Completed
NCT03844906Phase 1Completed
NCT03770780Phase 1Completed
NCT03771586Phase 1Completed

Competing Products

15 competing products in Huntington's Disease

See all competitors
ProductCompanyStageHype Score
AFQ056 + PlaceboNovartisPhase 2
52
RO7234292 (RG6042)RochePhase 2
52
RG6496 + PlaceboRochePhase 1
33
PF-02545920 + PF-02545920PfizerPhase 2
51
20 mg BID of PF-02545920PfizerPhase 2
51
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
51
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
30
TetrabenazineLundbeckApproved
82
BN82451B + PlaceboIpsenPhase 2
49
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mgIonis PharmaceuticalsPhase 1/2
38
WVE-120102 + PlaceboWaVe Life SciencesPhase 1/2
36
WVE-120101 + PlaceboWaVe Life SciencesPhase 1/2
36
SAGE-718Supernus PharmaceuticalsPhase 3
72
OMS643762 + PlaceboOmeros CorporationPhase 2
47
VX15/2503 + PlaceboVaccinexPhase 2
44

Other Products from Supernus Pharmaceuticals

ZULRESSO®Approved
80
APOKYNApproved
80
SPN-812Approved
80
SPN-812Approved
80
100mg SPN-812 + PlaceboApproved
80